Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.56 |
| ▸ | TLR2 | O60603 | 2/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7780471 | 1.00 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL9659933 | 1.00 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL9659930 | 1.00 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL7533568 | 1.00 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL7533567 | 1.00 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL9658685 | 1.00 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL7782934 | 1.00 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL7780475 | 1.00 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL9658679 | 1.00 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA | |
| SCHEMBL293572 | 1.00 | PRCP (0.56) | PRCPTLR2DPP7NAAAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346669-A1 | PROCESS FOR DYEING KERATIN FIBERS USING A DIRECT DYE AND A SACCHARINATE SALT AND COMPOSITION COMPRISING THEM | L'OREAL (FR) | 2023-11-02 | — | — | US | disclosed |
| EP-1135398-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | Monsanto Technology LLC (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-0664119-B1 | Tape transdermal use easily detachable from the skin | NITTO DENKO CORP (JP) | 2001-08-29 | — | — | EP | disclosed |
| US-6218563-B1 | Cyanophosphonamides and method for preparation | MONSANTO COMPANY | 2001-04-17 | — | — | US | disclosed |
| WO-2000032611-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | MONSANTO TECHNOLOGY LLC (US) | 2000-06-08 | — | — | WO | disclosed |
| US-5814032-A | DRUG DELIVERY WITH TAPE FOR TRANSDERMAL DELIVERY AND MULTILAYER BANDAGES | NITTO DENKO CORPORATION (JP) | 1998-09-29 | — | — | US | disclosed |
| EP-0664119-A2 | Tape transdermal use easily detachable from the skin | NITTO DENKO CORPORATION (JP) | 1995-07-26 | — | — | EP | disclosed |
| EP-0309624-B1 | COMPOSITION FOR ENHANCING PERCUTANEOUS ADMINISTRATION OF MEDICINE | NITTO DENKO CORPORATION (JP) | 1992-03-11 | — | — | EP | disclosed |
| US-5059628-A | Proline or prolinol ester to enhance absorption | NITTO ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1991-10-22 | — | — | US | disclosed |
| EP-0309624-A1 | Composition for enhancing percutaneous administration of medicine | NITTO DENKO CORPORATION (JP) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346669-A1 | PROCESS FOR DYEING KERATIN FIBERS USING A DIRECT DYE AND A SACCHARINATE SALT AND COMPOSITION COMPRISING THEM | KRT18, DSG1, KRTCAP2 | PRCP 3339/4885TLR2 3540/4885DPP7 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.